NCT04917224

Study of LUNG Stereotactic Adaptive Ablative Radiotherapy

Phase II Study of LUNG Stereotactic Adaptive Ablative Radiotherapy for Central and Ultracentral Tumors

• Status: Withdrawn
• Phase: N/A
• Study type: Interventional
• Enrollment: 0 (actual)
• Sponsor: Baptist Health South Florida · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Accepted

Summary

The proposed study expands on the principles of SBRT (Stereotactic Body Radiation Therapy) and SABR (Stereotactic Ablative Radiotherapy) for centrally located NSCLC (Non-Small Cell Lung Cancer) to further optimize outcomes in this patient population with utilization of the adaptive workflow to maintain tumor control rates but decrease the incidence and grade of treatment-related toxicities.

Conditions

• Lung Cancer
• Lung Tumor

Interventions

Type	Name	Description
RADIATION	Stereotactic Adaptive Ablative Radiotherapy at 50 Gy (Gray)	Cohort A will include 30 patients with central tumors; the dose regimen prescribed is 50 Gy (Gray) in 5 fractions with a 40 hour inter-fraction interval.
RADIATION	Stereotactic Adaptive Ablative Radiotherapy at 60 Gy (Gray)	Cohort B will include 30 patients with ultra-central tumors; the dose regimen prescribed is 60 Gy (Gray) in 8 fractions on consecutive days.

Timeline

• Start date: 2022-05-02
• Primary completion: 2031-10-01
• Completion: 2032-10-01
• First posted: 2021-06-08
• Last updated: 2023-09-26